Perrigo (PRGO)

NYSE Health Care Pharmaceuticals S&P SmallCap 600
$15.85
+0.14 (+0.89%)
Close of Nov 06, 2026 · end-of-day data
Next earnings date
Not scheduled yet
No report date announced in the next three weeks.
Consensus EPS estimate
—
Shown once a date is announced.
Last report (Nov 04)
$0.60 vs $0.56 est.
Surprise +7.1%

Earnings surprise history

reported EPS vs consensus
ReportedQuarterEPS estimateReported EPSSurprise
Nov 04, 2026Sep/2026$0.56$0.60+7.1%

Our record of PRGO's reports since we began tracking; it grows each quarter.

Latest results, in brief

All PRGO 8-K briefs →
Nov 4, 6:44 AM ET

Perrigo Q3 net sales fall 5.2%; Core 2026 adjusted EPS outlook cut to $2.15 to $2.35

Negative earnings 2.02

Perrigo reported third-quarter 2026 net sales of $989 million, down 5.2% from a year earlier, and a GAAP net loss of $27.5 million. The company cut its Core full-year 2026 adjusted EPS outlook to $2.15 to $2.35 from $2.25 to $2.55, citing softer consumer demand, retailer inventory positioning and Europe. It also agreed to sell its Infant Formula business for up to $175 million and expects a $275 million to $375 million impairment loss in the fourth quarter.

  • All In adjusted diluted EPS was $0.60 versus $0.80 a year earlier, down 25.0%; Core adjusted EPS was $0.61, down 9.0%.
  • Full-year 2026 Core adjusted EPS outlook is $2.15 to $2.35, down from $2.25 to $2.55; All In outlook is $2.25 to $2.45, up from $2.00 to $2.30 and reflects the Infant Formula divestiture.
  • Infant Formula sale carries $40 million in upfront cash at closing plus up to $135 million contingent on net sales milestones through 2030.
  • Expected impairment loss of $275 million to $375 million to be recognized in the fourth quarter of 2026.
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.

Quarter endedRevenueYoYEPS (diluted)YoYNet incomeNet margin
Sep 2026$988.60M-5.2% $-0.20-500.0% -$27.50M-2.8%
Jun 2026$1.02B-3.2% $0.53— $74.50M7.3%
Mar 2026$969.20M-7.2% $-2.87— -$398.60M-41.1%
Dec 2025$1.11B-2.5% $-10.24— -$1.42B-127.8%
Sep 2025$1.04B-4.1% $0.05— $7.50M0.7%
Jun 2025$1.06B-0.9% $-0.06— -$8.40M-0.8%
Mar 2025$1.04B-3.5% $-0.05-600.0% -$6.40M-0.6%
Dec 2024$1.14B-1.6% $-0.32— -$44.50M-3.9%

From Perrigo's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.

Annual results

Fiscal yearRevenueGrowthEPS (diluted)GrowthNet margin
FY2025$4.25B-2.8% $-10.29—-33.5%
FY2024$4.37B-6.1% $-1.25—-3.9%
FY2023$4.66B+4.6% $-0.09—-0.3%
FY2022$4.45B+7.6% $-1.04—-3.2%
FY2021$4.14B+1.2% $-0.52—-1.7%

Frequently asked questions

When is Perrigo's next earnings date?

Perrigo has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.

What did Perrigo earn last quarter?

For the quarter ended Sep 2026, Perrigo reported diluted EPS of $-0.20 (-500.0% year over year) on revenue of $988.60M (-5.2%).

Where do these numbers come from?

Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.

Not investment advice. Figures can be restated by the company in later filings.